Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuo Ma

Showing results (231-240 of 253) with videos related to

Pageof 26
Sort By:
The Lancet. Oncology|January 17, 2017
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.
Cancers|July 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CARTNicole J Altomare, Megan M Herr, Nisha M Nair, et al.
Blood Advances|October 22, 2025
Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortiumMegan Melody, Natalie Grover, Stephanie Franco, et al.
The New England Journal of Medicine|January 24, 2014
Idelalisib and rituximab in relapsed chronic lymphocytic leukemiaRichard R Furman, Jeff P Sharman, Steven E Coutre, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2019
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019William G Wierda, John C Byrd, Jeremy S Abramson, et al.
Blood Advances|March 26, 2024
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapyReem Karmali, Rushad Machhi, Narendranath Epperla, et al.
Blood Advances|August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN StudyNirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.
Pageof 26

Showing results (231-240 of 253) with videos related to

Sort By:
Pageof 26
The Lancet. Oncology|January 17, 2017
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.
Cancers|July 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CARTNicole J Altomare, Megan M Herr, Nisha M Nair, et al.
Blood Advances|October 22, 2025
Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortiumMegan Melody, Natalie Grover, Stephanie Franco, et al.
The New England Journal of Medicine|January 24, 2014
Idelalisib and rituximab in relapsed chronic lymphocytic leukemiaRichard R Furman, Jeff P Sharman, Steven E Coutre, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2019
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019William G Wierda, John C Byrd, Jeremy S Abramson, et al.
Blood Advances|March 26, 2024
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapyReem Karmali, Rushad Machhi, Narendranath Epperla, et al.
Blood Advances|August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN StudyNirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.
Pageof 26